Wilson I Gonsalves

List of Publications by Year
in descending order

394	5,525	94269 37	138251 58
papers	citations	h-index	g-index

400	400	400	5513
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing. Annals of Pharmacotherapy, 2023, 57, 29-35.	0.9	0
2	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	3.3	43
3	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	3.3	12
4	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	3.3	3
5	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	2.0	5
6	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	2.0	5
7	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	3.3	7
8	Melflufen for multiple myeloma: a promise unfulfilled?. Lancet Haematology,the, 2022, 9, e82-e84.	2.2	8
9	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio â‰¥100. Leukemia, 2022, 36, 1429-1431.	3.3	8
10	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplantation, 2022, , .	1.3	0
11	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer Journal, 2022, 12, 59.	2.8	3
12	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2022, 63, 2422-2427.	0.6	2
13	Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma. American Journal of Hematology, 2022, , .	2.0	6
14	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice, 2022, , OP2100789.	1.4	0
15	Impact of belantamab mafodotinâ€induced ocular toxicity on outcomes of patients with advanced multiple myeloma. British Journal of Haematology, 2022, 199, 95-99.	1.2	14
16	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2022, 40, e20001-e20001.	0.8	0
17	Sarcopenia identified by computed tomography (CT) imaging using a machine learningâ€“based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2022, 40, 110-110.	0.8	1
18	Ageism in the t(11;14) Subtype of Multiple Myeloma. Acta Haematologica, 2021, 144, 6-7.	0.7	2

#	Article	IF	Citations
19	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	1.3	1
20	Outcomes of multiple myeloma patients with <scp>del 17p</scp> undergoing autologous stem cell transplantation. American Journal of Hematology, 2021, 96, E35-E38.	2.0	2
21	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	1.1	4
22	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	1.1	3
23	Autologous stem cell transplantation for multiple myeloma patients aged â‰¥ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150.	1.3	15
24	Implications of detecting serum monoclonal protein by MASSâ€fix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	1.2	21
25	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as firstâ€line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	2.0	13
26	Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. Clinical Lung Cancer, 2021, 22, 67-70.	1.1	33
27	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	1.3	5
28	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 309.e1-309.e5.	0.6	1
29	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	0.6	2
30	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. Leukemia Research Reports, 2021, 15, 100242.	0.2	2
31	Practical management and assessment of primary plasma cell leukemia in the novel agent era. Cancer Treatment and Research Communications, 2021, 28, 100414.	0.7	1
32	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	3.3	8
33	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	2.0	12
34	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	2.5	9
35	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	1.4	12
36	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	1.4	16

#	Article	IF	Citations
37	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, 50.	2.8	25
38	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 355-360.	0.2	5
39	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2021, 39, e20016-e20016.	0.8	0
40	Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience.. Journal of Clinical Oncology, 2021, 39, e20000-e20000.	0.8	1
41	Assessment of fixedâ€duration therapies for treatmentâ€naÃ¯ve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
42	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	1.4	32
43	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.2	9
44	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplantation and Cellular Therapy, 2021, 27, 589.e1-589.e6.	0.6	3
45	Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effect. Nature Metabolism, 2021, 3, 954-968.	5.1	28
46	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Advances, 2021, 5, 2753-2759.	2.5	13
47	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leukemia and Lymphoma, 2021, 62, 3011-3018.	0.6	2
48	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology, 2021, 96, 1131-1136.	2.0	21
49	Disease outcomes and biomarkers of progression in smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	1.2	12
50	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplantation and Cellular Therapy, 2021, 27, 770.e1-770.e7.	0.6	6
51	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. Cancer Treatment and Research Communications, 2021, 29, 100444.	0.7	5
52	Comparison of the current renal staging, progression and response criteria to predict renal survival in <scp>AL</scp> amyloidosis using a <scp>Mayo</scp> cohort. American Journal of Hematology, 2021, 96, 446-454.	2.0	8
53	Supportive care in multiple myeloma: Current practices and advances. Cancer Treatment and Research Communications, 2021, 29, 100476.	0.7	5
54	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	2.0	6

#	Article	IF	Citations
55	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. Blood, 2021, 138, 1639-1639.	0.6	3
56	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. Blood, 2021, 138, 2707-2707.	0.6	0
57	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNÎ²-NIS). Blood, 2021, 138, 1333-1333.	0.6	0
58	Prognostic Role of IL-6 in POEMS Syndrome. Blood, 2021, 138, 2700-2700.	0.6	0
59	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio â‰¥100. Blood, 2021, 138, 1617-1617.	0.6	0
60	Disrupting the Reverse Warburg Effect As a Therapeutic Strategy in Multiple Myeloma. Blood, 2021, 138, 2649-2649.	0.6	1
61	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. Blood, 2021, 138, 819-819.	0.6	1
62	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. Blood, 2021, 138, 3805-3805.	0.6	0
63	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer Journal, 2021, 11, 186.	2.8	8
64	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	0.6	1
65	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	0.6	0
66	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. Blood, 2021, 138, 2711-2711.	0.6	2
67	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma-Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	0.6	0
68	Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2021, 138, 2735-2735.	0.6	2
69	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood, 2021, 138, 3774-3774.	0.6	1
70	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	0.6	0
71	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	0.6	0
72	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	0.6	0

#	Article	IF	Citations
73	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	0.6	0
74	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	0.6	0
75	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. Blood, 2021, 138, 3838-3838.	0.6	1
76	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	2.8	62
77	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	1.4	25
78	Ibrutinib monotherapy outside of clinical trial setting in WaldenstrÃ¶m macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	1.2	41
79	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. American Journal of Hematology, 2020, 95, E8-E10.	2.0	10
80	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	2.0	14
81	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.2	8
82	Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	2.0	37
83	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	2.0	4
84	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	2.0	33
85	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	3.3	40
86	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	3.3	15
87	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	3.3	29
88	Colon perforation in multiple myeloma patients â€“ A complication of highâ€dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	1.3	3
89	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	2.8	3
90	Predictors of short-term survival in WaldenstrÃ¶m Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	0.6	2

#	Article	IF	Citations
91	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	2.0	17
92	In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer & Metabolism, 2020, 8, 29.	2.4	15
93	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	2.8	12
94	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Advances, 2020, 4, 5425-5430.	2.5	16
95	Reductive amination of Î±-Ketoglutarate in metabolite extracts results in glutamate overestimation. Journal of Chromatography A, 2020, 1623, 461169.	1.8	2
96	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	1.3	8
97	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1402-1405.	2.0	4
98	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	2.8	8
99	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal, 2020, 10, 55.	2.8	36
100	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	1.3	5
101	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a â€˜graft versus hostâ€™-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	1.3	1
102	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	2.0	12
103	Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. Scientific Reports, 2020, 10, 10250.	1.6	19
104	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal, 2020, 10, 20.	2.8	26
105	The Impact of Proliferating Polyclonal Plasma Cells on Outcome after Autologous Stem Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, S239.	2.0	0
106	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	2.8	18
107	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	2.0	35
108	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.2	15

#	Article	IF	Citations
109	Of lions, shar-pei, and doughnuts: a tale retold. Blood, 2020, 135, 1074-1076.	0.6	2
110	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	3.3	27
111	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances, 2020, 4, 322-326.	2.5	8
112	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. Blood, 2020, 136, 52-53.	0.6	4
113	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. Blood, 2020, 136, 48-49.	0.6	2
114	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 36-37.	0.6	4
115	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	0.6	4
116	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	0.6	1
117	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	0.6	3
118	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. Blood, 2020, 136, 22-23.	0.6	1
119	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	2.5	20
120	Characteristics and outcome of patients with MYD88 wild-type WaldenstrÃ¶m Macroglobulinemia.. Journal of Clinical Oncology, 2020, 38, 8550-8550.	0.8	3
121	Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation.. Journal of Clinical Oncology, 2020, 38, e20506-e20506.	0.8	0
122	Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy.. Journal of Clinical Oncology, 2020, 38, e20510-e20510.	0.8	1
123	Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. Journal of Clinical Oncology, 2020, 38, 8516-8516.	0.8	0
124	Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).. Journal of Clinical Oncology, 2020, 38, e19112-e19112.	0.8	1
125	Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.. Journal of Clinical Oncology, 2020, 38, e20515-e20515.	0.8	0
126	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	0.6	0

#	Article	IF	Citations
127	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	0.6	0
128	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	0.6	0
129	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	0.6	0
130	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	0.6	0
131	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. Blood, 2020, 136, 21-22.	0.6	0
132	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	0.6	0
133	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged â‰¥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	0.6	0
134	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	0.6	1
135	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	0.6	0
136	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). Blood, 2020, 136, 29-30.	0.6	2
137	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Blood, 2020, 136, 41-42.	0.6	0
138	WaldenstrÃ¶m Macroglobulinemia in the Very Elderly (â‰¥75 years):Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	0.6	8
139	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 306-311.	2.0	18
140	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 587-594.	1.3	9
141	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.	1.3	7
142	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	1.3	81
143	Tenâ€year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	1.2	40
144	Autologous Stem Cell Transplantation in Patients with AL Amyloidosis with Impaired Renal Function. Biology of Blood and Marrow Transplantation, 2019, 25, S389-S390.	2.0	0

#	Article	IF	Citations
145	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	1.4	9
146	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Advances, 2019, 3, 1226-1229.	2.5	7
147	Characteristics of longâ€term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer, 2019, 125, 3574-3581.	2.0	7
148	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology, 2019, 94, 1020-1026.	2.0	36
149	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology, 2019, 94, 1066-1071.	2.0	14
150	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	3.3	22
151	Autologous Stem Cell Transplant for IgM Related AL Amyloidosis. Biology of Blood and Marrow Transplantation, 2019, 25, S388-S389.	2.0	0
152	Crystalglobulin-Induced Nephropathy and Keratopathy. Kidney Medicine, 2019, 1, 71-74.	1.0	10
153	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. Bone Marrow Transplantation, 2019, 54, 1898-1907.	1.3	1
154	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2039-2050.	1.3	9
155	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2960-2967.	0.6	4
156	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation, 2019, 25, 1520-1525.	2.0	9
157	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. British Journal of Haematology, 2019, 185, 701-707.	1.2	17
158	Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. Haematologica, 2019, 104, 2061-2074.	1.7	27
159	Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL). Biology of Blood and Marrow Transplantation, 2019, 25, S30.	2.0	2
160	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	2.8	38
161	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. Bone Marrow Transplantation, 2019, 54, 1775-1779.	1.3	9
162	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	2.0	15

#	Article	IF	Citations
163	Substratification of patients with newly diagnosed standardâ€risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	1.2	12
164	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia, 2019, 33, 1268-1272.	3.3	7
165	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. American Journal of Hematology, 2019, 94, E141-E143.	2.0	17
166	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia, 2019, 33, 1273-1277.	3.3	12
167	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometryâ€"Verified Typing. Mayo Clinic Proceedings, 2019, 94, 472-483.	1.4	59
168	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	2.5	41
169	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Advances, 2019, 3, 744-750.	2.5	28
170	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia Research, 2019, 87, 106264.	0.4	0
171	Clinically significant delay in engraftment with day -1 melphalan prior to stem cell infusion in myeloma patients receiving stem cell transplant.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e301-e302.	0.2	0
172	Venetoclax For The Treatment of Translocation AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e332.	0.2	1
173	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	2.0	11
174	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2019, 25, e108-e111.	2.0	20
175	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081.	1.3	7
176	Primary systemic amyloidosis in patients with WaldenstrÃ¶m macroglobulinemia. Leukemia, 2019, 33, 790-794.	3.3	28
177	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia, 2019, 33, 730-738.	3.3	20
178	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	3.3	36
179	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia, 2019, 33, 531-536.	3.3	72
180	Prevalence and survival of smouldering WaldenstrÃ¶m macroglobulinaemia in the United States. British Journal of Haematology, 2019, 184, 1014-1017.	1.2	20

#	Article	IF	Citations
181	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. Blood, 2019, 134, 4334-4334.	0.6	1
182	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. Blood, 2019, 134, 4386-4386.	0.6	2
183	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 864-864.	0.6	13
184	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. Blood, 2019, 134, 1905-1905.	0.6	2
185	Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).. Journal of Clinical Oncology, 2019, 37, 7509-7509.	0.8	4
186	Rituximab-based maintenance therapy in WaldenstrÃ¶m macroglobulinemia: A case control study.. Journal of Clinical Oncology, 2019, 37, 7559-7559.	0.8	8
187	Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome.. Journal of Clinical Oncology, 2019, 37, 8019-8019.	0.8	2
188	Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. Journal of Clinical Oncology, 2019, 37, 8039-8039.	0.8	31
189	Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.. Journal of Clinical Oncology, 2019, 37, e19519-e19519.	0.8	2
190	Plasmacytomas: many faces of one disease, or many diseases with one face?. Oncotarget, 2019, 10, 257-258.	0.8	0
191	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 455-464.	1.4	16
192	Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.. Journal of Clinical Oncology, 2019, 37, 8011-8011.	0.8	0
193	Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC).. Journal of Clinical Oncology, 2019, 37, 8031-8031.	0.8	2
194	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity.. Journal of Clinical Oncology, 2019, 37, 8034-8034.	0.8	0
195	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. Blood, 2019, 134, 4505-4505.	0.6	0
196	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	0.6	0
197	WaldenstrÃ¶m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	0.6	0
198	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	0.6	0

#	Article	IF	Citations
199	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. Blood, 2019, 134, 3080-3080.	0.6	0
200	Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Blood, 2019, 134, 3160-3160.	0.6	4
201	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833.	0.6	0
202	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. Blood, 2019, 134, 1904-1904.	0.6	0
203	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. Blood, 2019, 134, 1697-1697.	0.6	4
204	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. Blood, 2019, 134, 5532-5532.	0.6	0
205	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. Blood, 2019, 134, 3171-3171.	0.6	1
206	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197.	0.6	0
207	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	0.6	1
208	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	3.3	8
209	Outcomes of Autologous Hematopoietic Stem Cell Transplant in Sporadic Late Onset Nemaline Myopathy with Associated Monoclonal Gammopathy of Unknown Significance. Biology of Blood and Marrow Transplantation, 2018, 24, S124-S125.	2.0	1
210	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	3.3	64
211	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.	1.7	10
212	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	2.0	14
213	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	2.0	21
214	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrÃ¶m macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	0.8	71
215	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia, 2018, 32, 1414-1420.	3.3	20
216	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	3.3	28

#	Article	IF	Citations
217	Second Autologous Hematopoietic Stem Cell Transplant as Salvage Therapy for Relapsed Multiple Myeloma: A Global Treatment Option for Eligible Patients. Acta Haematologica, 2018, 139, 45-46.	0.7	6
218	Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity. Cell Reports, 2018, 22, 1365-1373.	2.9	85
219	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	1.3	4
220	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Mayo Clinic Proceedings, 2018, 93, 56-58.	1.4	16
221	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. British Journal of Haematology, 2018, 182, 71-77.	1.2	15
222	Efficacy of VDT PACEâ€like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	2.0	49
223	MYD88 mutation status does not impact overall survival in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	2.0	57
224	Combination therapy incorporating Bclâ€2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). European Journal of Haematology, 2018, 100, 215-217.	1.1	52
225	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology, 2018, 93, 17-22.	2.0	11
226	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. Journal of Clinical Oncology, 2018, 36, 1323-1329.	0.8	100
227	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer Journal, 2018, 8, 106.	2.8	16
228	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	2.8	64
229	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	2.8	29
230	Utility and prognostic value of ¹⁸Fâ€FDG positron emission tomographyâ€computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	2.0	19
231	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	2.5	23
232	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	2.5	23
233	Defining Lymphoplasmacytic Lymphoma. American Journal of Clinical Pathology, 2018, 150, 168-176.	0.4	5
234	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14

#	Article	IF	Citations
235	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
236	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	2.8	18
237	Serum free light chain measurements to reduce 24â€h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	2.0	3
238	Predictors of symptomatic hyperviscosity in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	2.0	24
239	59-Year-Old Man With Fatigue, Weight Loss, and Hepatomegaly. Mayo Clinic Proceedings, 2018, 93, 1525-1529.	1.4	1
240	Kidney Involvement of Patients with WaldenstrÃ¶m Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1037-1046.	2.2	46
241	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	2.8	171
242	Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. JCI Insight, 2018, 3, .	2.3	39
243	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	0.6	10
244	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	0.6	1
245	Daratumumab-based therapies in patients with AL amyloidosis.. Journal of Clinical Oncology, 2018, 36, 8053-8053.	0.8	2
246	Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. Oncotarget, 2018, 9, 34582-34594.	0.8	3
247	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 8023-8023.	0.8	0
248	Natural history of delp53 multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20017-e20017.	0.8	0
249	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).. Journal of Clinical Oncology, 2018, 36, 8045-8045.	0.8	0
250	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. Journal of Clinical Oncology, 2018, 36, 8030-8030.	0.8	0
251	Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.	0.6	0
252	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0

#	Article	IF	Citations
253	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	0.6	0
254	Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. Blood, 2018, 132, 3182-3182.	0.6	0
255	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	0.6	0
256	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
257	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.	0.6	0
258	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	0.6	0
259	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	0.6	1
260	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.	0.6	0
261	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	0.6	0
262	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	0.6	0
263	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	0.6	1
264	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. Blood, 2018, 132, 5594-5594.	0.6	0
265	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. Blood, 2018, 132, 3227-3227.	0.6	0
266	Should we measure clonal circulating plasma cells in light chain amyloidosis?. Oncotarget, 2018, 9, 35607-35608.	0.8	1
267	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	0.6	0
268	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	0.6	0
269	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. Blood, 2018, 132, 3436-3436.	0.6	0
270	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	0.6	1

#	Article	IF	Citations
271	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2018, 132, 4615-4615.	0.6	0
272	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. Blood, 2018, 132, 3160-3160.	0.6	2
273	Prognosis of Patients with WaldenstrÃ¶m Macroglobulinemia: A Simplified Model. Blood, 2018, 132, 4152-4152.	0.6	1
274	Patient-Reported Outcome Driven Case Management System for Hematology â€" a Prospective Study. Blood, 2018, 132, 719-719.	0.6	1
275	Estimating the annual volume of hematologic cancer cases per hematologistâ€"oncologist in the United States: are we treating rare cancers too rarely?. Leukemia and Lymphoma, 2017, 58, 251-252.	0.6	6
276	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine, 2017, 49, 545-551.	1.5	45
277	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. American Journal of Hematology, 2017, 92, 435-440.	2.0	16
278	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	0.6	50
279	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood, 2017, 129, 2111-2119.	0.6	249
280	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 40-41.	1.4	4
281	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	2.0	5
282	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. Vascular Medicine, 2017, 22, 121-127.	0.8	18
283	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology, 2017, 92, 668-673.	2.0	75
284	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	1.4	115
285	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. American Journal of Hematology, 2017, 92, 549-554.	2.0	24
286	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	3.4	110
287	Delineation of the timing of second-line therapy postâ€"autologous stem cell transplant in patients with AL amyloidosis. Blood, 2017, 130, 1578-1584.	0.6	21
288	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	1.2	15

#	Article	IF	Citations
289	POEMS syndrome: An elusive diagnosis. American Journal of Hematology, 2017, 92, 1269-1270.	2.0	1
290	Bortezomib Versus Non-Bortezomib Based Initial Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e140-e141.	0.2	0
291	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ¯ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	1.2	25
292	Efficacy of daratumumabâ€based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	2.0	25
293	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	1.4	4
294	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	0.6	54
295	The next generation of novel therapies for the management of relapsed multiple myeloma. Future Oncology, 2017, 13, 63-75.	1.1	11
296	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	1.2	10
297	Betaâ€blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	2.0	41
298	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	1.4	72
299	What are patientsâ€™ biggest concerns? A patient reported outcome case-management system.. Journal of Clinical Oncology, 2017, 35, 6572-6572.	0.8	3
300	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2017, 35, 8038-8038.	0.8	1
301	Factors predicting organ response in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8048-8048.	0.8	1
302	Natural history of t(11;14) multiple myeloma (MM).. Journal of Clinical Oncology, 2017, 35, 8014-8014.	0.8	1
303	The use of proteasome inhibitors among patients with POEMS syndrome.. Journal of Clinical Oncology, 2017, 35, e19530-e19530.	0.8	0
304	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8049-8049.	0.8	0
305	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8047-8047.	0.8	0
306	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. Journal of Clinical Oncology, 2017, 35, e19532-e19532.	0.8	0

#	Article	IF	Citations
307	Smoldering WaldenstrÃ¶mâ€™s macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2017, 35, 1573-1573.	0.8	0
308	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. Journal of Clinical Oncology, 2017, 35, 8032-8032.	0.8	0
309	Treatment approaches and outcomes in extramedullary plasmacytomas.. Journal of Clinical Oncology, 2017, 35, 8050-8050.	0.8	0
310	Effect of Surgical Intervention on Survival of Patients With Clinical N2 Nonâ€“Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 142-146.	0.6	3
311	Induction therapy preâ€autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	2.0	45
312	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research, 2016, 44, 32-39.	0.4	22
313	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 447-452.	0.2	24
314	Myelomatous Involvement of the Central Nervous System. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 644-654.	0.2	38
315	Systemic Immunoglobulin Light Chain Amyloidosisâ€“Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	1.4	43
316	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	2.0	76
317	Longâ€term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	2.0	57
318	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 101-108.	2.0	19
319	Nâ€terminal fragment of the typeâ€B natriuretic peptide (NTâ€proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	2.0	71
320	Clinical Features and Outcomes of Plasmacytoma: a National Cancer Database Study (2000 â€“ 2011). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S81-S82.	0.2	0
321	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May HarborMYD88L265P Mutations. American Journal of Clinical Pathology, 2016, 145, 843-851.	0.4	43
322	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1284-1289.	0.4	25
323	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	0.6	1
324	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	0.6	4

#	Article	IF	Citations
325	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	0.6	2
326	Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base. Blood, 2016, 128, 3249-3249.	0.6	1
327	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	0.6	1
328	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	0.6	3
329	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. Blood, 2016, 128, 3337-3337.	0.6	5
330	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. Blood, 2016, 128, 3444-3444.	0.6	1
331	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.	0.6	1
332	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. Journal of Clinical Oncology, 2016, 34, 8004-8004.	0.8	3
333	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. Journal of Clinical Oncology, 2016, 34, 8015-8015.	0.8	1
334	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.. Journal of Clinical Oncology, 2016, 34, 8035-8035.	0.8	0
335	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8053-8053.	0.8	0
336	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8017-8017.	0.8	0
337	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naÃ¯ve (TN) WaldenstrÃ¶m macroglobulinemia (WM).. Journal of Clinical Oncology, 2016, 34, 7552-7552.	0.8	1
338	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. Journal of Clinical Oncology, 2016, 34, 8062-8062.	0.8	0
339	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. Journal of Clinical Oncology, 2016, 34, 8016-8016.	0.8	0
340	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2960-2960.	0.6	15
341	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	0.6	0
342	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	0.6	0

#	Article	IF	Citations
343	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	0.6	0
344	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	0.6	0
345	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	0.6	0
346	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	0.6	0
347	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. Blood, 2016, 128, 5918-5918.	0.6	1
348	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	0.6	0
349	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	0.6	0
350	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	0.6	0
351	Outcome of Very Young (â‰¤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. Blood, 2016, 128, 5576-5576.	0.6	0
352	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	0.6	0
353	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2016, 128, 2267-2267.	0.6	0
354	Predictors of Survival in Multiple Myeloma Patients after Relapse from a Delayed Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, S137.	2.0	0
355	The use of novel agents in multiple myeloma patients with hepatic impairment. Future Oncology, 2015, 11, 501-510.	1.1	11
356	The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S239.	0.2	0
357	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	0.6	1
358	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.	0.6	5
359	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. Blood, 2015, 126, 3297-3297.	0.6	0
360	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. Blood, 2015, 126, 4176-4176.	0.6	0

#	Article	IF	Citations
361	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. Blood, 2015, 126, 5303-5303.	0.6	0
362	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. Blood, 2015, 126, 4370-4370.	0.6	0
363	Bortezomib-based combination regimens in myeloma: more is not necessarily better. Leukemia and Lymphoma, 2014, 55, 1439-1440.	0.6	0
364	Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S147.	0.2	7
365	Epstein-Barr Virus Infection in an Elderly Nonimmunocompromised Adult Successfully Treated with Rituximab. Case Reports in Hematology, 2014, 2014, 1-4.	0.3	3
366	Secondary Hemophagocytic Syndrome Associated with Richterâ€™s Transformation in Chronic Lymphocytic Leukemia. Case Reports in Hematology, 2014, 2014, 1-4.	0.3	0
367	Association Between Race and Survival of Patients With Nonâ€“Small-Cell Lung Cancer in the United States Veterans Affairs Population. Clinical Lung Cancer, 2014, 15, 152-158.	1.1	38
368	Drugs that affect blood coagulation, fibrinolysis, and hemostasis. Side Effects of Drugs Annual, 2014, 35, 617-631.	0.6	0
369	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute, 2014, 106, .	3.0	140
370	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. British Journal of Haematology, 2014, 167, 500-505.	1.2	81
371	Sarcoidosis Presenting with Pancytopenia. American Journal of Medicine, 2014, 127, e9-e10.	0.6	24
372	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood, 2014, 124, 907-912.	0.6	111
373	Early Mortality in Multiple Myeloma: Risk Factors and Impact on Population Outcomes. Blood, 2014, 124, 1320-1320.	0.6	9
374	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). Blood, 2014, 124, 304-304.	0.6	25
375	PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma. Blood, 2014, 124, 3382-3382.	0.6	4
376	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses. Blood, 2014, 124, 4780-4780.	0.6	0
377	Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients. Blood, 2014, 124, 4751-4751.	0.6	0
378	Improvement in Renal Function and Its Impact on Survival in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 3368-3368.	0.6	1

#	Article	IF	Citations
379	Gallbladder cancer-associated thrombotic microangiopathy. Future Oncology, 2013, 9, 1711-1715.	1.1	1
380	The New Oral Anticoagulants in Clinical Practice. Mayo Clinic Proceedings, 2013, 88, 495-511.	1.4	93
381	Visual Loss in Early-Stage Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2013, 31, e280-e282.	0.8	9
382	Chronic Eosinophilic Leukemiaâ€"Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma. Case Reports in Hematology, 2013, 2013, 1-4.	0.3	2
383	Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood, 2013, 122, 1746-1749.	0.6	21
384	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. Blood, 2013, 122, 754-754.	0.6	0
385	Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. Blood, 2013, 122, 2081-2081.	0.6	0
386	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. Blood, 2013, 122, 1842-1842.	0.6	0
387	Granulomatous Inflammation Detected by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in Patients With a Concurrent Diagnosis of Cancer. Journal of Bronchology and Interventional Pulmonology, 2012, 19, 176-181.	0.8	13
388	Systemic amyloidosis masquerading as iron deficiency anemia. Indian Journal of Gastroenterology, 2012, 31, 351-352.	0.7	0
389	Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer â€" A Veterans Affairs Cancer Registry analysis. Journal of Geriatric Oncology, 2011, 2, 209-214.	0.5	22
390	Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology, 2011, 78, 227-242.	2.0	33
391	Effect of Palliative Care Services on the Aggressiveness of End-of-Life Care in the Veteran's Affairs Cancer Population. Journal of Palliative Medicine, 2011, 14, 1231-1235.	0.6	70
392	Waiting in line for cancer treatments?. Gastrointestinal Cancer Research: GCR, 2011, 4, 147-9.	0.8	0
393	A 49-Year-Old Woman With Acute Respiratory Failure. Chest, 2010, 138, 224-227.	0.4	0
394	Effects of Volume and Site of Blood Draw on Blood Culture Results. Journal of Clinical Microbiology, 2009, 47, 3482-3485.	1.8	97